MarketGrader currently has a BUY rating on BOLT TECHNOLOGY CORP (BTJ), based on a final overall grade of 79.7 scored by the company's fundamental analysis. BOLT TECHNOLOGY CORP scores at the 99th percentile among all 5445 U.S. listed equities currently followed by MarketGrader. Our present rating dates to November 18, 2005, when it was upgraded from a HOLD. Relative to the Oil & Gas Equipment & Services sub-industry, which is comprised of 66 companies, BOLT TECHNOLOGY CORP's grade of 79.7 ranks seventh. The industry grade leader is GULFMARK OFFSHORE INC (GLF) with an overall grade of 85.8. Relative to the Oil & Gas Equipment & Services sub-industry which has returned 17.11% in the last six months, the stock has performed poorly, up 15.14%, albeit better than the S&P 500's 7.58%.
Regards,
frenchee
#board-4258 TSP Trend Timing: EFA (I), TLT (F), SPY (C), and VXF (S)
Recent BOLT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 08:06:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 08:05:16 PM
- Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/12/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:06:10 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:05:11 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/12/2026 08:14:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/12/2026 08:07:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:05:29 PM
- Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/12/2026 08:05:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/27/2026 12:22:05 AM
- Bolt Biotherapeutics to Participate in Upcoming March Conferences • GlobeNewswire Inc. • 02/24/2026 01:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 02/18/2026 01:11:16 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/13/2026 11:48:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:32:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 09:32:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2025 10:14:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 09:08:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 09:05:28 PM
- Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/12/2025 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2025 11:19:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2025 11:18:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2025 08:05:26 PM
- Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 • GlobeNewswire Inc. • 10/01/2025 08:05:00 PM
- Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2025 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/02/2025 08:05:36 PM
